SCHEMBL724725

SCHEMBL724725

COc1cc(-c2cc3nccc(-c4cnn(CC(N)=O)c4)c3o2)cc(OC)c1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAB2 O43741 2/20 0.42
ABL1 P00519 2/20 0.42
CSF1R P07333 2/20 0.42
LYN P07948 2/20 0.42
PRKAG1 P54619 2/20 0.42
SIK1 P57059 2/20 0.42
PRKAA1 Q13131 2/20 0.42
SIK2 Q9H0K1 2/20 0.42
SIK3 Q9Y2K2 2/20 0.42
PDE4C Q08493 1/20 0.38
ALDH1A1 P00352 1/20 0.37
CYP3A4 P08684 1/20 0.37
TGFBR1 P36897 1/20 0.37
TGFBR2 P37173 1/20 0.37
SYK P43405 3/20 0.36
MAP3K11 Q16584 1/20 0.36
IKBKE Q14164 2/20 0.35
TBK1 Q9UHD2 2/20 0.35
PDK2 Q15119 3/20 0.35
FYN P06241 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721506 0.92 PDE4C (0.39) PRKAB2ABL1CSF1RLYNPRKAG1
SCHEMBL722160 0.89 PDE4C (0.36) PRKAB2ABL1CSF1RLYNPRKAG1
SCHEMBL725161 0.86 PDE4C (0.42) PDE4CALDH1A1CYP3A4SYKIKBKE
SCHEMBL10266954 0.86 PDE4C (0.42) PRKAB2ABL1CSF1RLYNPRKAG1
SCHEMBL722258 0.83 JAK2 (0.39) PDE4CALDH1A1CYP3A4IKBKETBK1
SCHEMBL723668 0.83 PGK1 (0.41) PDE4CPTGESALOX5
SCHEMBL722228 0.81 PDE4C (0.43) PDE4CTGFBR2SYKFYNCYP1A1
SCHEMBL723546 0.81 JAK2 (0.44) PRKAB2CSF1RPRKAG1PRKAA1PDE4C
SCHEMBL723093 0.79 PDE4C (0.55) PDE4CALDH1A1CYP3A4SYKFYN
SCHEMBL15210341 0.77 CSF1R (0.45) PRKAB2ABL1CSF1RLYNPRKAG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB PRKAB2 1832/4885ABL1 66/4885CSF1R 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.